BioSyent Releases Financial Results for Q3 and YTD 2025

1 hour ago 1

Article content

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Comprehensive Income

In Canadian Dollars	Q3 2025	Q3 2024	% Change	YTD 2025	YTD 2024	% Change
Net Revenues	12,221,804	9,556,011	28%	33,380,060	26,234,213	27%
Cost of Goods Sold	2,954,884	2,069,596	43%	7,863,386	5,533,089	42%
Gross Profit	9,266,920	7,486,415	24%	25,516,674	20,701,124	23%
Operating Expenses and Finance Income/Costs	5,617,478	4,511,311	25%	15,965,050	13,169,535	21%
Net Income Before Tax	3,649,442	2,975,104	23%	9,551,624	7,531,589	27%
Tax (including Deferred Tax)	967,102	667,210	45%	2,531,180	1,874,679	35%
Net Income After Tax	2,682,340	2,307,894	16%	7,020,444	5,656,910	24%
Net Income After Tax % to Net Revenues	22%	24%		21%	22%
EBITDA¹	3,632,399	2,849,636	27%	9,594,195	7,101,900	35%
EBITDA¹ % to Net Revenues	30%	30%		29%	27%

Article content

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Financial Position

AS AT	September 30, 2025		December 31, 2024		% Change
ASSETS

Cash, cash equivalents and short-term investments	$	23,395,434	$	15,940,971	47%
Trade and other receivables		6,277,318		2,906,829	116%
Inventory		5,899,364		5,328,086	11%
Prepaid expenses and deposits		339,938		201,971	68%
Derivative asset		–		5,790	-100%
Loans receivable – current		57,240		87,433	-35%
CURRENT ASSETS		35,969,294		24,471,080	47%

Long term investments		5,400,816		10,103,571	-47%
Loans receivable – current		84,003		141,140	-40%
Deferred tax asset		342,359		401,166	-15%
Property and equipment		1,039,978		1,200,992	-13%
Intangible assets		4,948,931		5,041,501	-2%
TOTAL NON CURRENT ASSETS		11,816,087		16,888,370	-30%
TOTAL ASSETS	$	47,785,381	$	41,359,450	16%

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES	$	7,106,740	$	5,405,106	31%
NON CURRENT LIABILITIES		775,772		951,159	-18
Long term debt		–		–	0%
Total Equity		39,902,869		35,003,185	14%
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	47,785,381	$	41,359,450	16%

Article content

EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.
A reconciliation of EBITDA to NIAT for the three months, nine months, and trailing twelve months ended September 30, 2025 and 2024 is provided in the table below:

Article content

	Three Months (Q3) Ended September 30		Nine Months (YTD) Ended September 30		Trailing Twelve Months (TTM) Ended September 30
	2025	2024	2025	2024	2025	2024
EBITDA	3,632,399	2,849,636	9,594,195	7,101,900	11,835,307	8,752,201
Add: Interest Income	231,389	256,890	621,333	828,498	881,421	1,170,681
Less: Depreciation – Property, Equipment	(66,353)	(70,298)	(201,335)	(209,107)	(273,448)	(286,071)
Amortization of Intangible Assets	(135,852)	(46,545)	(424,694)	(144,521)	(588,901)	(188,909)
Interest Expense	(12,141)	(14,579)	(37,875)	(45,181)	(51,846)	(61,575)
Income Tax Expense	(967,102)	(667,210)	(2,531,180)	(1,874,679)	(3,168,895)	(2,278,626)
NIAT	2,682,340	2,307,894	7,020,444	5,656,910	8,633,638	7,107,701

Article content

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: [email protected]
Phone: 905-206-0013
Web: www.biosyent.com

Article content

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Article content